Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug.

Keller JJ, Vehreschild MJ, Hvas CL, Jørgensen SM, Kupciskas J, Link A, Mulder CJ, Goldenberg SD, Arasaradnam R, Sokol H, Gasbarrini A, Hoegenauer C, Terveer EM, Kuijper EJ, Arkkila P; UEG working group of the Standards and Guidelines initiative Stool banking for FMT.

United European Gastroenterol J. 2019 Dec;7(10):1408-1410. doi: 10.1177/2050640619887579. Epub 2019 Nov 14. No abstract available.

2.

Central venous catheter-related bloodstream infections in patients with hematological malignancies: Comparison of data from a clinical registry and a randomized controlled trial.

Schalk E, Teschner D, Hentrich M, Böll B, Panse J, Schmidt-Hieber M, Vehreschild MJGT, Biehl LM.

Infect Control Hosp Epidemiol. 2019 Dec 10:1-3. doi: 10.1017/ice.2019.335. [Epub ahead of print] No abstract available.

PMID:
31818338
3.

Lactose drives Enterococcus expansion to promote graft-versus-host disease.

Stein-Thoeringer CK, Nichols KB, Lazrak A, Docampo MD, Slingerland AE, Slingerland JB, Clurman AG, Armijo G, Gomes ALC, Shono Y, Staffas A, Burgos da Silva M, Devlin SM, Markey KA, Bajic D, Pinedo R, Tsakmaklis A, Littmann ER, Pastore A, Taur Y, Monette S, Arcila ME, Pickard AJ, Maloy M, Wright RJ, Amoretti LA, Fontana E, Pham D, Jamal MA, Weber D, Sung AD, Hashimoto D, Scheid C, Xavier JB, Messina JA, Romero K, Lew M, Bush A, Bohannon L, Hayasaka K, Hasegawa Y, Vehreschild MJGT, Cross JR, Ponce DM, Perales MA, Giralt SA, Jenq RR, Teshima T, Holler E, Chao NJ, Pamer EG, Peled JU, van den Brink MRM.

Science. 2019 Nov 29;366(6469):1143-1149. doi: 10.1126/science.aax3760.

PMID:
31780560
4.

Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study.

Wilcox MH, Cornely OA, Guery B, Longshaw C, Georgopali A, Karas A, Kazeem G, Palacios-Fabrega JA, Vehreschild MJGT.

Open Forum Infect Dis. 2019 Nov 6;6(11):ofz436. doi: 10.1093/ofid/ofz436. eCollection 2019 Nov.

5.

Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild MJGT, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A; Mucormycosis ECMM MSG Global Guideline Writing Group.

Lancet Infect Dis. 2019 Dec;19(12):e405-e421. doi: 10.1016/S1473-3099(19)30312-3. Epub 2019 Nov 5. Review.

PMID:
31699664
6.

The Role of Microbiota in Preventing Multidrug-Resistant Bacterial Infections.

Khodamoradi Y, Kessel J, Vehreschild JJ, Vehreschild MJGT.

Dtsch Arztebl Int. 2019 Oct 4;116(40):670-676. doi: 10.3238/arztebl.2019.0670.

7.

A necessary discussion after transmission of multidrug-resistant organisms through faecal microbiota transplantations.

Kuijper EJ, Allegretii J, Hawkey P, Sokol H, Goldenberg S, Ianiro G, Gasbarrini A, Kump P, Costello SP, Keller J, Vehreschild MJGT.

Lancet Infect Dis. 2019 Nov;19(11):1161-1162. doi: 10.1016/S1473-3099(19)30545-6. No abstract available.

PMID:
31657769
8.

International consensus conference on stool banking for faecal microbiota transplantation in clinical practice.

Cammarota G, Ianiro G, Kelly CR, Mullish BH, Allegretti JR, Kassam Z, Putignani L, Fischer M, Keller JJ, Costello SP, Sokol H, Kump P, Satokari R, Kahn SA, Kao D, Arkkila P, Kuijper EJ, Vehreschild MJG, Pintus C, Lopetuso L, Masucci L, Scaldaferri F, Terveer EM, Nieuwdorp M, López-Sanromán A, Kupcinskas J, Hart A, Tilg H, Gasbarrini A.

Gut. 2019 Dec;68(12):2111-2121. doi: 10.1136/gutjnl-2019-319548. Epub 2019 Sep 28. Review.

9.

Distinct impact of antibiotics on the gut microbiome and resistome: a longitudinal multicenter cohort study.

Willmann M, Vehreschild MJGT, Biehl LM, Vogel W, Dörfel D, Hamprecht A, Seifert H, Autenrieth IB, Peter S.

BMC Biol. 2019 Sep 18;17(1):76. doi: 10.1186/s12915-019-0692-y.

10.

Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn).

Salmanton-García J, Seidel D, Koehler P, Mellinghoff SC, Herbrecht R, Klimko N, Ráčil Z, Falces-Romero I, Ingram P, Benítez-Peñuela MÁ, Rodríguez JY, Desoubeaux G, Barać A, García-Vidal C, Hoenigl M, Mehta SR, Cheng MP, Klyasova G, Heinz WJ, Iqbal N, Krause R, Ostermann H, Penack O, Schalk E, Sheppard DC, Willinger B, Wisplinghoff H, Vehreschild JJ, Cornely OA, Vehreschild MJGT; FungiScope® ECMM/ISHAM Working Group .

J Antimicrob Chemother. 2019 Nov 1;74(11):3315-3327. doi: 10.1093/jac/dkz344.

PMID:
31393591
11.

Controlling intestinal colonization of high-risk haematology patients with ESBL-producing Enterobacteriaceae: a randomized, placebo-controlled, multicentre, Phase II trial (CLEAR).

Dimitriou V, Biehl LM, Hamprecht A, Vogel W, Dörfel D, Peter S, Schafhausen P, Rohde H, von Lilienfeld-Toal M, Klassert TE, Slickers P, Ehricht R, Slevogt H, Christ H, Hellmich M, Farowski F, Tsakmaklis A, Higgins PG, Seifert H, Vehreschild MJGT.

J Antimicrob Chemother. 2019 Jul 1;74(7):2065-2074. doi: 10.1093/jac/dkz124.

PMID:
31220256
12.

The impact of technical and clinical factors on fecal microbiota transfer outcomes for the treatment of recurrent Clostridioides difficile infections in Germany.

Peri R, Aguilar RC, Tüffers K, Erhardt A, Link A, Ehlermann P, Angeli W, Frank T, Storr M, Glück T, Sturm A, Rosien U, Tacke F, Bachmann O, Solbach P, Stallmach A, Goeser F, Vehreschild MJ; German Clinical Microbiome Study Group (GCMSG).

United European Gastroenterol J. 2019 Jun;7(5):716-722. doi: 10.1177/2050640619839918. Epub 2019 Mar 21.

13.

Treatment of (recurrent) Clostridioides difficile Infections in Children and Adults.

Kuijper EJ, Coia JE, Vehreschild MJGT, Keller J, Terveer L.

J Pediatr Gastroenterol Nutr. 2019 Aug;69(2):e57-e58. doi: 10.1097/MPG.0000000000002387. No abstract available.

PMID:
31169660
14.

Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis.

Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild MJGT, Bohlius J, Wisplinghoff H, Vehreschild JJ.

Clin Microbiol Infect. 2019 Oct;25(10):1200-1212. doi: 10.1016/j.cmi.2019.04.024. Epub 2019 Apr 27.

PMID:
31039444
15.

Usability of rectal swabs for microbiome sampling in a cohort study of hematological and oncological patients.

Biehl LM, Garzetti D, Farowski F, Ring D, Koeppel MB, Rohde H, Schafhausen P, Stecher B, Vehreschild MJGT.

PLoS One. 2019 Apr 15;14(4):e0215428. doi: 10.1371/journal.pone.0215428. eCollection 2019.

16.

Manipulation of the microbiota to eradicate multidrug-resistant Enterobacteriaceae from the human intestinal tract.

Kuijper EJ, Vendrik KEW, Vehreschild MJGT.

Clin Microbiol Infect. 2019 Jul;25(7):786-789. doi: 10.1016/j.cmi.2019.03.025. Epub 2019 Apr 6. No abstract available.

PMID:
30965098
17.

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.

Cornely OA, Vehreschild MJGT, Adomakoh N, Georgopali A, Karas A, Kazeem G, Guery B.

Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1187-1194. doi: 10.1007/s10096-019-03525-y. Epub 2019 Mar 25.

18.

Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis.

Alvarez-Silva C, Schierwagen R, Pohlmann A, Magdaleno F, Uschner FE, Ryan P, Vehreschild MJGT, Claria J, Latz E, Lelouvier B, Arumugam M, Trebicka J.

Front Immunol. 2019 Feb 8;10:69. doi: 10.3389/fimmu.2019.00069. eCollection 2019.

19.

Potential biomarkers to predict outcome of faecal microbiota transfer for recurrent Clostridioides difficile infection.

Farowski F, Solbach P, Tsakmaklis A, Brodesser S, Cruz Aguilar MR, Cornely OA, Dettmer K, Higgins PG, Suerbaum S, Jazmati N, Oefner PJ, Vehreschild MJGT; German Clinical Microbiome Study Group (GCMSG).

Dig Liver Dis. 2019 Jul;51(7):944-951. doi: 10.1016/j.dld.2019.01.012. Epub 2019 Jan 26.

PMID:
30770201
20.

Impact of single-room contact precautions on hospital-acquisition and transmission of multidrug-resistant Escherichia coli: a prospective multicentre cohort study in haematological and oncological wards.

Biehl LM, Higgins P, Wille T, Peter K, Hamprecht A, Peter S, Dörfel D, Vogel W, Häfner H, Lemmen S, Panse J, Rohde H, Klupp EM, Schafhausen P, Imirzalioglu C, Falgenhauer L, Salmanton-García J, Stecher M, Vehreschild JJ, Seifert H, Vehreschild MJGT.

Clin Microbiol Infect. 2019 Aug;25(8):1013-1020. doi: 10.1016/j.cmi.2018.12.029. Epub 2019 Jan 12.

PMID:
30641228
21.

Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®.

Seidel D, Meißner A, Lackner M, Piepenbrock E, Salmanton-García J, Stecher M, Mellinghoff S, Hamprecht A, Durán Graeff L, Köhler P, Cheng MP, Denis J, Chedotal I, Chander J, Pakstis DL, Los-Arcos I, Slavin M, Montagna MT, Caggiano G, Mares M, Trauth J, Aurbach U, Vehreschild MJGT, Vehreschild JJ, Duarte RF, Herbrecht R, Wisplinghoff H, Cornely OA.

Crit Rev Microbiol. 2019 Feb;45(1):1-21. doi: 10.1080/1040841X.2018.1514366. Epub 2019 Jan 10. Erratum in: Crit Rev Microbiol. 2019 Feb 18;:1.

PMID:
30628529
22.

Incidence of infections due to third generation cephalosporin-resistant Enterobacteriaceae - a prospective multicentre cohort study in six German university hospitals.

Rohde AM, Zweigner J, Wiese-Posselt M, Schwab F, Behnke M, Kola A, Obermann B, Knobloch JK, Feihl S, Querbach C, Gebhardt F, Mischnik A, Ihle V, Schröder W, Armean S, Peter S, Tacconelli E, Hamprecht A, Seifert H, Vehreschild MJGT, Kern WV, Gastmeier P; DZIF-ATHOS study group.

Antimicrob Resist Infect Control. 2018 Dec 27;7:159. doi: 10.1186/s13756-018-0452-8. eCollection 2018.

23.

An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila.

Cruz-Aguliar RM, Wantia N, Clavel T, Vehreschild MJGT, Buch T, Bajbouj M, Haller D, Busch D, Schmid RM, Stein-Thoeringer CK.

Digestion. 2019;100(2):127-138. doi: 10.1159/000494252. Epub 2018 Nov 13.

PMID:
30423561
24.

Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016.

Heimann SM, Vehreschild MJGT, Cornely OA, Heinz WJ, Grüner B, Silling G, Kessel J, Seidel D, Vehreschild JJ.

J Hosp Infect. 2019 Mar;101(3):339-346. doi: 10.1016/j.jhin.2018.11.003. Epub 2018 Nov 10.

PMID:
30423409
25.

Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).

Vehreschild MJGT, Taori S, Goldenberg SD, Thalhammer F, Bouza E, van Oene J, Wetherill G, Georgopali A.

Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):199. doi: 10.1007/s10096-018-3410-8.

26.

Vancomycin-resistant enterococci (VRE): a reason to isolate?

Vehreschild MJGT, Haverkamp M, Biehl LM, Lemmen S, Fätkenheuer G.

Infection. 2019 Feb;47(1):7-11. doi: 10.1007/s15010-018-1202-9. Epub 2018 Sep 3. Review.

PMID:
30178076
27.

Assessment of urinary 3-indoxyl sulfate as a marker for gut microbiota diversity and abundance of Clostridiales.

Farowski F, Els G, Tsakmaklis A, Higgins PG, Kahlert CR, Stein-Thoeringer CK, Bobardt JS, Dettmer-Wilde K, Oefner PJ, Vehreschild JJ, Vehreschild MJGT.

Gut Microbes. 2019;10(2):133-141. doi: 10.1080/19490976.2018.1502536. Epub 2018 Aug 17.

28.

Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection.

Biehl LM, Cruz Aguilar R, Farowski F, Hahn W, Nowag A, Wisplinghoff H, Vehreschild MJGT.

Infection. 2018 Dec;46(6):871-874. doi: 10.1007/s15010-018-1190-9. Epub 2018 Aug 14.

PMID:
30109576
29.

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).

Vehreschild MJGT, Taori S, Goldenberg SD, Thalhammer F, Bouza E, van Oene J, Wetherill G, Georgopali A.

Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2097-2106. doi: 10.1007/s10096-018-3344-1. Epub 2018 Aug 11. Erratum in: Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):199.

30.

BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection.

Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Gerhard M, Thoeringer CK, Vehreschild MJGT, Jazmati N, Rupp J, Manns MP, Bachmann O, Suerbaum S.

PLoS One. 2018 May 8;13(5):e0196977. doi: 10.1371/journal.pone.0196977. eCollection 2018.

31.

Evaluation of the Use of Rectal Swabs for Laboratory Diagnosis of Clostridium difficile Infection.

Jazmati N, Kirpal E, Piepenbrock E, Stelzer Y, Vehreschild MJGT, Seifert H.

J Clin Microbiol. 2018 Jun 25;56(7). pii: e00426-18. doi: 10.1128/JCM.00426-18. Print 2018 Jul.

32.

Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).

Rieger CT, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, Heinz WJ, Hentrich M, Maschmeyer G, Mayer K, Sandherr M, Silling G, Ullmann A, Vehreschild MJGT, von Lilienfeld-Toal M, Wolf HH, Lehners N; German Society of Hematology and Medical Oncology Infectious Diseases Working Group (AGIHO).

Ann Oncol. 2018 Jun 1;29(6):1354-1365. doi: 10.1093/annonc/mdy117. Review.

33.

Chlorhexidine-containing dressings in the prevention of central venous catheter-related bloodstream infections: A cost and resource utilization analysis.

Heimann SM, Biehl LM, Vehreschild JJ, Franke B, Cornely OA, Vehreschild MJGT.

Am J Infect Control. 2018 Sep;46(9):992-997. doi: 10.1016/j.ajic.2018.03.006. Epub 2018 Apr 13.

PMID:
29661631
34.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA.

Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.

35.

Guidance document for prevention of Clostridium difficile infection in acute healthcare settings.

Tschudin-Sutter S, Kuijper EJ, Durovic A, Vehreschild MJGT, Barbut F, Eckert C, Fitzpatrick F, Hell M, Norèn T, O'Driscoll J, Coia J, Gastmeier P, von Müller L, Wilcox MH, Widmer AF; Committee.

Clin Microbiol Infect. 2018 Oct;24(10):1051-1054. doi: 10.1016/j.cmi.2018.02.020. Epub 2018 Mar 2. Review.

36.

Economic burden and cost-effective management of Clostridium difficile infections.

Heimann SM, Cruz Aguilar MR, Mellinghof S, Vehreschild MJGT.

Med Mal Infect. 2018 Feb;48(1):23-29. doi: 10.1016/j.medmal.2017.10.010. Epub 2018 Jan 12. Review.

PMID:
29336929
37.

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.

Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT; EXTEND Clinical Study Group.

Lancet Infect Dis. 2018 Mar;18(3):296-307. doi: 10.1016/S1473-3099(17)30751-X. Epub 2017 Dec 19.

PMID:
29273269
38.

Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, Maschmeyer G, Schalk E, Vehreschild JJ, Vehreschild MJGT; AGIHO Working Group.

Ann Hematol. 2018 Jan;97(1):31-49. doi: 10.1007/s00277-017-3183-7. Epub 2017 Nov 24. Review.

39.

Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation.

Farowski F, Bücker V, Vehreschild JJ, Biehl L, Cruz-Aguilar R, Scheid C, Holtick U, Jazmati N, Wisplinghoff H, Cornely OA, Vehreschild MJGT.

Bone Marrow Transplant. 2018 Jan;53(1):52-57. doi: 10.1038/bmt.2017.203. Epub 2017 Nov 13.

PMID:
29131156
40.

FungiScope -Global Emerging Fungal Infection Registry.

Seidel D, Durán Graeff LA, Vehreschild MJGT, Wisplinghoff H, Ziegler M, Vehreschild JJ, Liss B, Hamprecht A, Köhler P, Racil Z, Klimko N, Sheppard DC, Herbrecht R, Chowdhary A, Cornely OA, FungiScope Group.

Mycoses. 2017 Aug;60(8):508-516. doi: 10.1111/myc.12631.

PMID:
28730644
41.

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.

Cornely OA, Leguay T, Maertens J, Vehreschild MJGT, Anagnostopoulos A, Castagnola C, Verga L, Rieger C, Kondakci M, Härter G, Duarte RF, Allione B, Cordonnier C, Heussel CP, Morrissey CO, Agrawal SG, Donnelly JP, Bresnik M, Hawkins MJ, Garner W, Gökbuget N; AmBiGuard Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2359-2367. doi: 10.1093/jac/dkx133.

42.

Determination of a Cutoff Time Point for Prophylactic Exchange of Central Venous Catheters for Prevention of Central Venous Catheter-Related Bloodstream Infections in Patients with Hematological Malignancies.

Schalk E, Biehl LM, Färber J, Schlüter D, Vehreschild MJGT, Fischer T.

Infect Control Hosp Epidemiol. 2017 Jul;38(7):888-889. doi: 10.1017/ice.2017.92. Epub 2017 May 18. No abstract available.

PMID:
28514979
43.

Screening and contact precautions - A survey on infection control measures for multidrug-resistant bacteria in German university hospitals.

Biehl LM, Bertz H, Bogner J, Dobermann UH, Kessel J, Krämer C, Lemmen S, von Lilienfeld-Toal M, Peter S, Pletz MW, Rohde H, Schmiedel S, Schubert S, Ullmann AJ, Fätkenheuer G, Vehreschild MJGT.

Antimicrob Resist Infect Control. 2017 Apr 13;6:37. doi: 10.1186/s13756-017-0191-2. eCollection 2017.

44.

Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry.

Durán Graeff L, Seidel D, Vehreschild MJ, Hamprecht A, Kindo A, Racil Z, Demeter J, De Hoog S, Aurbach U, Ziegler M, Wisplinghoff H, Cornely OA; FungiScope Group.

Mycoses. 2017 Apr;60(4):273-279. doi: 10.1111/myc.12595. Epub 2017 Feb 2.

PMID:
28150341
45.

Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis.

Vehreschild JJ, Heussel CP, Groll AH, Vehreschild MJGT, Silling G, Würthwein G, Brecht M, Cornely OA.

Eur Radiol. 2017 Aug;27(8):3275-3282. doi: 10.1007/s00330-016-4717-4. Epub 2017 Jan 12.

PMID:
28083695
46.

Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study.

Koehler P, Hamprecht A, Bader O, Bekeredjian-Ding I, Buchheidt D, Doelken G, Elias J, Haase G, Hahn-Ast C, Karthaus M, Kekulé A, Keller P, Kiehl M, Krause SW, Krämer C, Neumann S, Rohde H, La Rosée P, Ruhnke M, Schafhausen P, Schalk E, Schulz K, Schwartz S, Silling G, Staib P, Ullmann A, Vergoulidou M, Weber T, Cornely OA, Vehreschild MJ.

Int J Antimicrob Agents. 2017 Feb;49(2):218-223. doi: 10.1016/j.ijantimicag.2016.10.019. Epub 2016 Dec 12.

PMID:
27989379
47.

Disseminated Fusariosis in Immunocompromised Children-Analysis of Recent Cases Identified in the Global Fungiscope Registry.

Hassler A, Lieb A, Seidel D, Cesaro S, Greil J, Klimko N, Khostelidi S, Solopova G, Ogunc D, Durán Graeff L, Cornely OA, Vehreschild MJ, Lehrnbecher T.

Pediatr Infect Dis J. 2017 Feb;36(2):230-231. doi: 10.1097/INF.0000000000001396.

PMID:
27846057
48.

Draft Genome Sequences of Nine Clinical Isolates of Vancomycin-Resistant Enterococci.

Higgins PG, Koehler D, Chan JZ, Cornely OA, Fätkenheuer G, Gillis M, Pallen MJ, Tien J, Seifert H, Vehreschild MJ, Millard AD.

Genome Announc. 2016 Aug 18;4(4). pii: e00803-16. doi: 10.1128/genomeA.00803-16.

49.

The VITAL study: case control studies are hypothesis-generating - Authors' reply.

Cornely OA, Maher RM, Marty FM, Lee M, Vehreschild JJ, Vehreschild MJ.

Lancet Infect Dis. 2016 Aug;16(8):886-7. doi: 10.1016/S1473-3099(16)30192-X. No abstract available.

PMID:
27477971
50.

Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.

Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L, Eichhorst B, Fischer K, Cramer P, Fink AM, von Bergwelt-Baildon M, Stilgenbauer S, Hallek M, Cornely OA, Vehreschild MJ.

Oncoimmunology. 2016 Apr 22;5(6):e1150399. doi: 10.1080/2162402X.2016.1150399. eCollection 2016 Jun.

Supplemental Content

Loading ...
Support Center